| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.045 | 0.6 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |